Join to View Full Profile
10 Center Drive10/Room 12n226Bethesda, MD 20892
Dr. Karzai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Fatima Karzai is an oncologist located in Bethesda, MD, specializing in prostate cancer. She earned her medical degree from George Washington University School of Medicine and Health Sciences. Dr. Karzai has authored multiple publications focused on prostate cancer, including articles on gene signatures, prostate-specific membrane antigen imaging, and stem cell dynamics in castrate-resistant prostate cancer. Her research has contributed to journals such as Translational Andrology and Urology, Journal of Clinical Oncology, and European Urology Oncology. She is involved in clinical trials, actively serving as the principal investigator examining genomics, imaging, and therapeutic strategies in prostate cancer.
Education & Training
George Washington University School of Medicine and Health SciencesClass of 2005
Certifications & Licensure
MD State Medical License 2009 - 2026
DC State Medical License 2005 - 2009
VA State Medical License 2005 - 2009
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer Start of enrollment: 2019 Dec 04
Roles: Contact, Principal Investigator
- Precision-Based Genomics in Prostate Cancer Start of enrollment: 2021 Sep 14
Roles: Principal Investigator, Contact
- Men at High Genetic Risk for Prostate Cancer Start of enrollment: 2019 Mar 27
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing and Existing Data Suggest How to Mitigate Toxicity.Lisa M Cordes, Fatima Karzai, Ravi A Madan
European Urology Oncology. 2024-10-01 - Ferroptosis-related gene signature predicts prognosis and immune microenvironment in prostate cancer.Hao Wang, Dalang Fang, Jinxin Zhu, Lin Liu, Liang Xue
Translational Andrology and Urology. 2024-09-30 - 2 citationsQuantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide.Shruti U Gandhy, Fatima H Karzai, Marijo Bilusic, Sheri McMahon, Lisa M Cordes
European Urology Oncology. 2024-08-01
Journal Articles
- Tumor Cell Heterogeneity and Resistance; Report from the 2018 Coffey‐Holden Prostate Cancer Academy MeetingThomas A Hope, Kenneth J Pienta, Fatima Karzai, Simpa S Salami, Robert B Den, The Prostate
Press Mentions
Many Men with Metastatic Prostate Cancer Are Not Getting the Recommended Treatments, Study FindsFebruary 18th, 2025
Olaparib Shows Synergy with Durvalumab in mCRPCFebruary 9th, 2018
Olaparib, Durvalumab Combo Active in Prostate CancerFebruary 17th, 2017- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
